文献速递血栓与止血

直接口服抗凝药治疗肿瘤相关静脉血栓栓塞症:系统评价与Meta分析

Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis.
PubMed 文献 · Blood · 2020-01-01

该系统评价与Meta分析比较直接口服抗凝药(DOACs)与低分子量肝素(LMWHs)在肿瘤合并急性静脉血栓栓塞症(VTE)患者中的疗效与安全性。主要分析纳入2607例患者,DOACs组复发VTE风险非显著低于LMWHs组(RR 0.68,95%CI 0.39-1.17),大出血风险非显著高于LMWHs组(RR 1.36,95%CI 0.55-3.35)。结论认为DOACs是有效治疗选择,但高出血风险患者需谨慎。

要点

  • 肿瘤合并急性VTE患者中,DOACs组复发VTE风险非显著低于LMWHs组(RR 0.68,95%CI 0.39-1.17)。
  • DOACs组大出血风险非显著高于LMWHs组(RR 1.36,95%CI 0.55-3.35),临床相关非大出血风险亦非显著升高(RR 1.63,95%CI 0.73-3.64)。
  • 两组全因死亡风险相当(RR 0.96,95%CI 0.68-1.36),结论提示高出血风险患者使用DOACs需谨慎。

核心结论

  • DOACs是肿瘤合并急性VTE患者的有效治疗选择,但高出血风险患者需谨慎。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE、Embase、Cochrane对照试验中心注册库及会议论文集,纳入比较DOACs与LMWHs的随机对照试验,主要分析共2607例患者。

主要发现

  • DOACs组复发VTE风险非显著低于LMWHs组(RR 0.68,95%CI 0.39-1.17)。
  • DOACs组大出血风险非显著高于LMWHs组(RR 1.36,95%CI 0.55-3.35)。
  • DOACs组临床相关非大出血风险非显著高于LMWHs组(RR 1.63,95%CI 0.73-3.64)。
  • DOACs组复发VTE或大出血复合终点风险非显著低于LMWHs组(RR 0.86,95%CI 0.60-1.23)。
  • 两组全因死亡风险相当(RR 0.96,95%CI 0.68-1.36),治疗期间及偶然发现VTE患者中结果一致。

临床怎么用

  • 作者认为DOACs是肿瘤合并急性VTE患者的有效治疗选择,但高出血风险患者需谨慎。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent results. This systematic review and meta-analysis compared the efficacy and safety of DOACs and low-molecular-weight heparins (LMWHs) in these patients. MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and conference proceedings were searched to identify relevant randomized controlled trials. Additional data were obtained from the original authors to homogenize definitions for all study outcomes. The primary efficacy and safety outcomes were recurrent VTE and major bleeding, respectively. Other outcomes included the composite of recurrent VTE and major bleeding, clinically relevant nonmajor bleeding (CRNMB), and all-cause mortality. Summary relative risks (RRs) were calculated in a random effects meta-analysis. In the primary analysis comprising 2607 patients, the risk of recurrent VTE was nonsignificantly lower with DOACs than with LMWHs (RR, 0.68; 95% CI, 0.39-1.17). Conversely, the risks of major bleeding (RR, 1.36; 95% CI, 0.55-3.35) and CRNMB (RR, 1.63; 95% CI, 0.73-3.64) were nonsignificantly higher. The risk of the composite of recurrent VTE or major bleeding was nonsignificantly lower with DOACs than with LMWHs (RR, 0.86; 95% CI, 0.60-1.23). Mortality was comparable in both groups (RR, 0.96; 95% CI, 0.68-1.36). Findings were consistent during the on-treatment period and in those with incidental VTE. In conclusion, DOACs are an effective treatment option for patients with cancer and acute VTE, although caution is needed in patients at high risk of bleeding.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Mulder FI, Bosch FTM, Young AM, et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood. 2020. PMID: 32396939. doi:10.1182/blood.2020005819

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。